Menopausal Hot Flashes Market Size (2024 - 2029)

Menopausal Hot Flashes Market Analysis

The Menopausal Hot Flashes Market size is estimated at USD 6.91 billion in 2024, and is expected to reach USD 8.82 billion by 2029, growing at a CAGR of 5.02% during the forecast period (2024-2029).

Menopausal vasomotor symptoms (MVS), or hot flashes and night sweats, are often considered the cardinal symptoms of menopause. MVS are episodes of profuse heat accompanied by sweating and flushing, experienced predominantly around the head, neck, chest, and upper back.

The increasing incidence of vasomotor symptoms in menopausal women is expected to increase the utilization of drugs such as Climara, Delestrogen, and Elestrin, which is expected to drive market growth over the forecast period.

For instance, according to an article published in December 2023 in the Journal of the Menopause Society, an online study that contains 12,268 postmenopausal women from different countries, such as Brazil, Canada, Mexico, and four Nordic countries (Denmark, Finland, Norway, and Sweden), the prevalence of moderate to severe VMS was about 15.6%. Hence, the high prevalence of VMS across the globe is expected to drive the growth of the market over the forecast period.

According to the same article mentioned above, the highest prevalence of vasomotor symptoms was seen in Brazil, at 36%, and the lowest was in Nordic countries, at 11.6%. The severity of the symptoms in the participants affected their sleep negatively. Many women sought medical advice, but around 56.9% of the participants were not receiving treatment for their VMS. Hence, the high prevalence of menopausal vasomotor symptoms across the world is expected to increase the demand for hormonal therapy and non-hormonal therapies, which may ultimately drive the growth of the market over the forecast period.

The new researches are focused on the treatment of menopausal symptoms, targeting brain-based receptors to decrease side effects such as breast pain, acne, and hirsutism, which further increases patient compliance.

For instance, in May 2023, the US Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Hence, the launch of such novel products is expected to increase the accessibility for menopausal drugs, which may further drive the growth of the market over the forecast period.

Hence, the rising advancements in the development of novel drugs that target the receptors situated in the brain, such as neurokinin-1 and neurokinin-3, which reduce the body temperature and treat menopausal hot flashes in women who have contraindications to menopausal hormone therapy (MHT), is expected to accelerate the market growth over the forecast period.

Menopausal Hot Flashes Industry Segmentation

Menopausal hot flashes are the symptoms of menopause. They refer to uncomfortable feelings of warmth occurring during the menopause transition. Hot flashes are the most common symptom of perimenopause, a condition where ovaries gradually make less estrogen.

The menopausal hot flashes market is segmented by treatment type (hormonal treatment [estrogen, progesterone, and estrogen-progesterone combination] and non-hormonal treatment [antidepressant and other non-hormonal treatments]) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market sizes and forecasts in terms of value (USD) for all the above segments.